Comparative Study
Journal Article
Add like
Add dislike
Add to saved papers

Diagnosis of cholangiocarcinoma: a case series and literature review.

INTRODUCTION: Cholangiocarcinoma is a rare neoplasm of the bile ducts. Risk factors include primary sclerosing cholangitis, Caroli's disease, infection, liver flukes, and chronic typhoid. Improvements in imaging and surgical techniques may allow for earlier diagnosis and improvements in patient survival.

METHODS: A retrospective review of patients referred to a single center, and a literature review.

RESULTS: Of 23 patients 14 were male, 9 female; mean age 64 years. Mean survival time was 621 days. Stage I, II, III and IV patients had mean survival times of 1120.5, 117.5, 479.5, and 448.9 days, respectively. Patients with resectable disease had improved survival (964.5 days) compared to non-surgically treated (174.4 days) and unresectable patients (558.1 days).

CONCLUSIONS: Despite advances in imaging techniques and surgical care, overall survival of cholangiocarcinoma remains poor. Early recognition and minimization of delay may allow for definitive surgical therapy (complete resection) and improved survival.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

Related Resources

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app